Bioscience Co. Allegedly Hid Volatility Risks From Investors
A company purportedly focused on using traditional Chinese medicine to treat conditions including autism spectrum disorder faces a proposed investor class action alleging it downplayed the risk it would be probed...To view the full article, register now.
Already a subscriber? Click here to view full article